BS_PQVTB6BB
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 10.611038107752956
- age_years
- 7.863
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.357
- E2F_TARGETS+0.351
- G2M_CHECKPOINT+0.285
- WNT_BETA_CATENIN_SIGNALING+0.271
- NOTCH_SIGNALING+0.222
- KRAS_SIGNALING_DN+0.163
- SPERMATOGENESIS+0.127
- PANCREAS_BETA_CELLS+0.108
- MYC_TARGETS_V1+0.038
- DNA_REPAIR-0.007
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.529
- IL6_JAK_STAT3_SIGNALING-0.495
- TNFA_SIGNALING_VIA_NFKB-0.494
- ALLOGRAFT_REJECTION-0.472
- INTERFERON_ALPHA_RESPONSE-0.470
- COMPLEMENT-0.443
- INFLAMMATORY_RESPONSE-0.418
- PROTEIN_SECRETION-0.415
- ANDROGEN_RESPONSE-0.409
- APOPTOSIS-0.393
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208946 | — | — | 0.933 |
| 2 | BS_44A3ES23 | medulloblastoma | — | 0.925 |
| 3 | SRR8518343 | — | E | 0.922 |
| 4 | C3N-03886 | — | cohortMD1 | 0.922 |
| 5 | BS_3V3KE3VT | medulloblastoma | — | 0.920 |
| 6 | 065d8d7a-c241-4a24-8f77-2cb5a4341f35 | — | — | 0.911 |
| 7 | TCGA-D6-6827-01A-11R-1915-07 | — | — | 0.911 |
| 8 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.910 |
| 9 | 20040095.TNBC | — | E | 0.908 |
| 10 | BS_VAAHBH60 | EPN | Supratentorial EPN | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.357 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.351 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.285 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.271 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.222 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.163 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.127 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.108 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.038 | Inavolisib | — uncovered |